Prexton Therapeutics completes phase 1 clinical trial

Please login or
register
29.09.2016

Prexton Therapeutics, a biopharmaceutical company developing novel therapeutics for the treatment of CNS conditions, announced the successful completion of the phase 1 clinical trial for their lead compound for the treatment  Parkinson. A phase 2 trial for Parkinson’s disease patients is due in the first half of 2017.

Prexton Therapeutics began their first clinical study in March 2016. The biotech company recently announced the successful completion of their first study. A total of 64 healthy volunteers were enrolled to evaluate several doses of PXT002331, which has proved safe and well tolerated.

This study was the first in man clinical trial for an mGluR4 positive allosteric modulator. The randomized, double-blind, placebo controlled single and multiple ascending dose studies were designed to assess safety and tolerability of XT002331 dosed orally. It was completed on time and showed that PXT002331 is safe and well tolerated at doses well above those that produce robust effects in Parkinson’s disease animal models.

"We are very happy with the completion of the first clinical trial with our lead compound PXT002331, which is the first mGluR4 PAM ever to enter a clinical phase. This is an important step for Prexton,” said Francois Conquet, CEO of Prexton Therapeutics. “This achievement ensures Prexton is in a solid position for a successful clinical development of PXT002331 as a novel treatment for Parkinson’s disease and we look forward to moving in that direction.”

Prexton’s innovative approach in the treatment of Parkinson’s is unique as it stimulates a compensatory neuronal system that is not impacted by the disease. Competitors in this indication mostly target the dopaminergic system, which does not address all symptoms and is accompanied by a number of adverse effects. Prexton’s compound activates a specific target of the glutamatergic system, with the goal of providing a robust therapeutic effect without these adverse events. Prexton’s first in class treatment has the potential to offer a better benefit/risk ratio for Parkinson’s patients than existing therapies.

The company aims to develop a group of first-in-class molecules that target the metabotropic Glutamate Receptor 4 (mGluR4), a protein belonging to the metabotropic glutamate receptor family. Preclinical data shows compelling evidence of the efficacy of Prexton’s molecule. It has the potential to alleviate motor complications by modulating glutamate over activity in the central nervous system of Parkinson patients.

A phase 2 clinical trial in Parkinson’s disease patients will take place in the first half of 2017, with the aim of demonstrating the effectiveness of the compound.

(Press release)

0Comments

More news about

Prexton Therapeutics SA

Company profiles on startup.ch

Prexton Therapeutics SA

rss